By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over the last 12 months, one Lineage Cell Therapeutics, Inc. executives and directors bought into shares at market prices, about $24,000 in total, and none of them sold.
The largest purchase came from Culley Brian M (CEO), about $24,000. C-suite participation is part of the picture here.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters. Big money check: 326 institutions held LCTX as of Q2 2026, and more funds bought than sold.
Are insiders buying or selling LCTX stock?
In the last 12 months Lineage Cell Therapeutics, Inc. insiders made open-market purchases worth about $24,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in LCTX?
The most recent open-market insider trade in LCTX was filed on 2026-03-12.
How many institutions own LCTX?
326 investment managers reported holding LCTX in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded LCTX?
No congressional trades in LCTX were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).